Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease.

about

Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients.

P2860

Q45324737-DA5EC347-904A-49D3-ADD2-22C29319A590 Q55508515-C25A6113-BE82-4DD6-8D23-B91BE01A726C

P2860

Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease.

Item

http://www.wikidata.org/entity/Q40277831

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Elbasvir/grazoprevir does not ...... nd pre-existing renal disease.

@en

type

Item

label

Elbasvir/grazoprevir does not ...... nd pre-existing renal disease.

@en

prefLabel

Elbasvir/grazoprevir does not ...... nd pre-existing renal disease.

@en

P1476

Elbasvir/grazoprevir does not ...... nd pre-existing renal disease.

@en

P2093

Annette Bruchfeld

http://www.w3.org/2001/XMLSchema#string

Barbara Haber

http://www.w3.org/2001/XMLSchema#string

David Roth

http://www.w3.org/2001/XMLSchema#string

Eliav Barr

http://www.w3.org/2001/XMLSchema#string

Michael N Robertson

http://www.w3.org/2001/XMLSchema#string

Peggy Hwang

http://www.w3.org/2001/XMLSchema#string

Wayne Greaves

http://www.w3.org/2001/XMLSchema#string

P2860

Update on current management of chronic kidney disease in patients with HIV infection

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre

Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease.

The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.

Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?

Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories.

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

P31

scholarly article

P356

10.1111/HEPR.12899

http://www.w3.org/2001/XMLSchema#string

P50

K. Rajender Reddy

P577

2017-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28334495

http://www.w3.org/2001/XMLSchema#string

Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease.

about

P2860

P2860

Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P31

P356

P50

P577

P698